Cedar Mountain Advisors’s Kura Oncology KURA Stock Holding History

Cedar Mountain Advisors’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.95K	Hold	542	–	–	﹤0.01%	640
2026 Q1	$4.41K	Buy	+542	New	+$4.66K	﹤0.01%	694

Other funds holding KURA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Cedar Mountain Advisors's KURA Position: Q2 2026 in Review

Cedar Mountain Advisors held its Kura Oncology (KURA) position steady in Q2 2026 at 542 shares worth $5.95K. The position accounts for ﹤0.01% of the portfolio, ranked #640.

Cedar Mountain Advisors first reported a position in KURA in Q1 2026 and has held it in 2 quarters since. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

Cedar Mountain Advisors held 542 shares of Kura Oncology worth $5.95K as of Q2 2026.
Cedar Mountain Advisors left its Kura Oncology share count unchanged in Q2 2026.
Kura Oncology made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #640 holding.
Cedar Mountain Advisors first reported a position in Kura Oncology in Q1 2026 and has held it in 2 quarters since.
221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.